Skip to main content

Table 1 Prognostic value of Glypican family genes in The Cancer Genome Atlas database

From: Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

Gene

No. of events (%)

MST (days)

Crude HR

95% CI

Crude

P value

Adjusted HR

95% CIa

Adjusted

P valuea

GPC1

 Low

36/56(64.3%)

518

1

 

1

 

 High

33/56(58.9%)

511

0.986(0.610–1.594)

0.955

1.120 (0.661–1.896)

0.674

GPC2

 Low

41/56(73.2%)

481

1

 

1

 

 High

28/56(50.0%)

634

0.589(0.362–0.959)

0.031

0.449(0.258–0.782)

0.005

GPC3

 Low

38/56(67.9%)

473

1

 

1

 

 High

31/56(55.4%)

614

0.568(0.349–0.925)

0.021

0.531(0.309–0.914)

0.022

GPC4

 Low

35/56(62.5%)

517

1

 

1

 

 High

34/56(60.7%)

592

1.066(0.659–1.723)

0.794

1.252(0.744–2.105)

0.397

GPC5

 Low

35/56(62.5%)

485

1

 

1

 

 High

34/56(60.7%)

593

0.577(0.351–0.948)

0.028

0.525(0.306–0.902)

0.020

GPC6

 Low

37/56(66.1%)

485

1

 

1

 

 High

32/56(57.1%)

603

0.647(0.393–1.063)

0.083

0.891(0.501–1.585)

0.693

  1. Abbreviations: MST median survival time, HR hazard ratio, CI confidence interval
  2. aAdjusted for histologic grade, targeted molecular therapy, radiation therapy and radical resection